Our laboratory is focused on the development of platform-based vaccines and therapeutics to address the threat of emerging infectious diseases. We employ a rational design approach, targeting specific antigens from pathogens to elicit robust immune responses. Our vaccine development pipeline includes subunit, DNA, and RNA-based platforms, while our therapeutic development efforts focus on neutralizing antibodies, siRNA, and gene-based therapies. These candidates undergo comprehensive preclinical evaluation to assess their safety and efficacy. Ultimately, our goal is to advance these products into clinical trials and establish stockpiles for rapid deployment in the event of a biodisaster.